Xenikos
is a Netherlands-based biopharmaceutical company that develops and commercializes novel therapies for the treatment of acute graft-versus-host disease... Read moreXenikos
is a Netherlands-based biopharmaceutical company that develops and commercializes novel therapies for the treatment of acute graft-versus-host disease... Read more
News
Jun 27, 2022
FinanzNachrichten
Xenikos: Xenikos B.V.: Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study Evaluating T-Guard in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
Sep 15, 2021
Global Legal Chronicle
Xenikos: Xenikos' 40 Million Convertible Debt Financing
Jul 19, 2021
FinanzNachrichten
Xenikos: Xenikos B.V.: Xenikos Announces T-Guard Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives
Dec 26, 2018
Pharmabiz
Xenikos: Xenikos partners with BMT CTN to conduct phase 3 trial to test T─Guard in acute graft─versus─host disease
Dec 20, 2018
centralcharts
Press Release: Xenikos : DGAP-News: Xenikos partners with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a U.S.-based Phase 3 trial to test T-Guard(R) in acute graft-versus-host disease
Sep 28, 2018
BioPortfolio
Xenikos: Xenikos BV Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 17092018 Prices from USD $250
May 15, 2018
BioCentury
Xenikos: Xenikos raises $30M series B
Nov 02, 2017
FinanzNachrichten
Xenikos: Xenikos B.V.: Xenikos Announces Data From Phase I/II Trial With T-Guard For The Treatment Of Steroid-Resistant Acute GVHD To Be Presented At ASH Annual Meeting
Jan 03, 2017
BioPortfolio
Xenikos: Dutch firm awarded 1m credit extension to develop immunotherapy drug
Xenikos Competitors
1
2
3
4
5
6
7
8
9
10